Navigation Links
Bayer and Onyx Begin Enrollment in Phase 3 Trial of Nexavar in Combination With Chemotherapy Agent Capecitabine for Patients With Advanced Breast Cancer
Date:2/24/2011

overall survival, time to progression, and safety. For more information regarding this trial refer to www.clinicaltrials.gov (NCT 01234337).

"Nexavar has demonstrated efficacy in advanced kidney cancer and unresectable liver cancer and we are committed to evaluating Nexavar in a variety of treatment settings and tumor types," said Ted W. Love, M.D., Executive Vice President and Head of Research and Development and Technical Operations for Onyx Pharmaceuticals.

About the Nexavar Clinical Program in Breast Cancer

The TIES (Trials to Investigate the Effects of Sorafenib in Breast Cancer) program is a cooperative group-sponsored clinical development program evaluating Nexavar in a variety of treatment settings for patients with breast cancer conducted by investigators and oncology cooperative groups. Among these clinical trials are two ongoing randomized Phase 2 studies, including a trial to evaluate Nexavar plus gemcitabine or capecitabine in the second-line setting following progression on bevacizumab and a trial to evaluate Nexavar plus docetaxel and/or letrozole in the first-line metastatic breast cancer setting.

About Breast Cancer

Breast cancer was the most commonly diagnosed cancer among women worldwide in 2007-2008 (approximately 1.3 million cases), and the second leading cause of cancer-related death among women (approximately 465,000 deaths). It is the most commonly diagnosed cancer among women in the United States (1 in 4 cancer diagnoses is breast cancer). There are approximately 200,000 new cases of breast cancer in the United States and 430,000 in Europe each year. More than 40,000 women in the United States and more than 130,000 in Europe die of breast cancer each year. (l)(ll)(lll)

About Nexavar

Nexavar is approved in the U.S. for the treatment of patients with unresectable liver cancer and for the treatment of pat
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
4. Bayer HealthCare Celebrates 20th Anniversary of Kogenate(R) Product Line and 8 Billion IU Milestone at 2008 WFH World Congress
5. Cell Therapeutics, Inc. (CTI) to Hold Conference Call to Discuss Agreement With Bayer Schering Pharma for Access to Phase III Zevalin(R) FIT Trial Data
6. Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer
7. FDA Approves Bayer HealthCares Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A
8. Bayer Announces Upcoming Presentations of Campath(R) and Leukine(R) Data at the 50th Annual Meeting of the American Society of Hematology
9. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
10. Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting
11. Bayer Announces New Data on Novel Anti-cancer Compound BAY 73-4506
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye, today announced ... Wall to the Company,s Board. Mr. ... Boston -based investment firm, for more than ... Board of Directors, and chair of the Corporate Governance Committee ...
(Date:9/2/2015)... THOUSAND OAKS, Calif. , Sept. 2, 2015 ... announced the submission of a Marketing Authorization Application ... the centralized procedure for etelcalcetide (formerly AMG 416) ... adult patients with chronic kidney disease (CKD) on ... first calcimimetic agent that can be administered intravenously. ...
(Date:9/2/2015)... , Sept. 2, 2015 Research and ... of the "An Introduction to Medical Device ... 2-3, 2015)" conference to their offering. ... introduction to the regulations and requirements that apply ... highly interactive, using real life examples and state-of- ...
Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 2Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 3Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 4Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 5Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 6Amgen Submits Marketing Authorization Application For Novel Intravenous Calcimimetic Etelcalcetide (AMG 416) To The European Medicines Agency 7An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2
... Approach to Blood ... Pressure Management, ... in the discovery and development of novel small,molecule therapeutics, announced ... statistically significant,blood pressure reductions in a Phase 2a study in ...
... MDVN ) today announced that data from an ... antagonist, MDV3100, will be presented,in an oral presentation at ... in Chicago., Session title: New Targeted Strategies ... time: Monday, June 2 at 11:30 a.m. Central Time ...
Cached Medicine Technology:Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 2Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 3Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 4Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 5Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 6Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 7Pharmacopeia's First-in-Class Investigational Therapy PS433540 Achieves Statistically Significant Reductions in Blood Pressure in Hypertensive Patients 8Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 2Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting 3
(Date:9/2/2015)... ... ... article published August 12 by International Business Times, a new bill was signed ... in cases meant to decide if a police officer used deadly or excessive force in ... and New York City that absolved police officers of charges in the deaths of two ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... from the Abraham and Mildred Goldstein Charitable Trust to establish the Abraham and ... gift comes six months after WCHN recruited nationally known gynecologic oncologist Thomas J. ...
(Date:9/2/2015)... ... 02, 2015 , ... In “Failure Lab: Weight Loss Surgery was Never the ... writer Akela Stanfield detailed her lifelong struggle with obesity that eventually led her to ... seen herself as someone who would lose weight through sheer self-control, the dawning realization ...
(Date:9/2/2015)... ... September 02, 2015 , ... Healtec® LLC hired ... departure of Kristen Dietz, former Chief Operations Officer. Shaun Carpenter MD, FAPWCA, ... welcoming Mr. Salot: “ Stanley H. Salot Jr , our new President and ...
(Date:9/2/2015)... ... September 02, 2015 , ... Density measurement is used in ... sample handling makes density measurements more efficient and error-free. The new METTLER TOLEDO ... workflow and the advantages compared to manual sample handling. , The Evolution of ...
Breaking Medicine News(10 mins):Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 2Health News:Article on Recent Grand Jury Law Brings Increased Accountability to Wrongful Death Cases, says the Law Offices of Burg & Brock 3Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 2Health News:Western Connecticut Health Network Receives $1 Million Gift to Establish Ovarian Cancer Research Endowment 3Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:Healtec® Announces Executive Leadership Change 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 2Health News:New Video from METTLER TOLEDO Shows the Advantages of Sample Handling Automation in Density Determination 3
... CONSHOHOCKEN, Pa., March 13 Apollo Health Street has ... Payer segment in the prestigious Black Book of Outsourcing ... Apollo Health Street, states, "We appreciate the recognition from ... is an independent validation of our commitment to excellence.""The ...
... Human Genome Sciences, Inc. (Nasdaq: HGSI ... and Company 29th Annual Health Care Conference will be ... http://www.newscom.com/cgi-bin/prnh/20080416/HGSLOGO ) , A member of Human ... overview on Wednesday, March 18, 2009 from 8:45 to ...
... PHILADELPHIA, March 13 Lead Counsel for Plaintiffs in ... the following:, UNITED STATES DISTRICT COURT, ... IN RE: SCHERING-PLOUGH CORPORATION SECURITIES LITIGATION, ... , ATTENTION PURCHASERS OF SCHERING-PLOUGH CORPORATION SECURITIES ...
... Bank, N.A.BASKING RIDGE, N.J., March 13 Hooper Holmes (Amex: ... fourth quarter and year ended December 31, 2008. For the ... to $47.4 million compared to $51.4 million in the fourth ... $1.2 million for the fourth quarter of 2008, or $0.02 ...
... up your keys has its down sideSAN FRANCISCO, March 13 ... Gerontology (Medical Sciences) indicate that convincing older drivers to give ... idea.The study of 660 adults aged 63 to 97 showed ... more likely to die over a three-year period than their ...
... Stock Exchange Bell-Ringing, Yoko Ono Lennon Event at the UN, ,and ... ... New York, NY (PRWEB) March 13, 2009 -- Autism ... a series of national and international events to mark the second ...
Cached Medicine News:Health News:Apollo Health Street Has Earned the Number One Spot in the Healthcare Payer Segment for BPO Services 2Health News:Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. 2Health News:Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. 3Health News:Settlement Hearing on Schering-Plough Corporation Securities Litigation to be Held on June 1, 2009 at 2:00 P.M. 4Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 2Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 3Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 4Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 5Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 6Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 7Health News:Hooper Holmes Announces Fourth Quarter and Year-End 2008 Results 8Health News:Drive or Die 2Health News:Drive or Die 3Health News:Autism Speaks Celebrates Second Annual World Autism Awareness Day with an Array of International Events on April 2 2Health News:Autism Speaks Celebrates Second Annual World Autism Awareness Day with an Array of International Events on April 2 3Health News:Autism Speaks Celebrates Second Annual World Autism Awareness Day with an Array of International Events on April 2 4Health News:Autism Speaks Celebrates Second Annual World Autism Awareness Day with an Array of International Events on April 2 5
Merocel Ophthalmic Products provide the surgeon with fiber free products for fluid,control and safe cleaning of fine microsurgical instruments. The exclusive Merocel,material is highly absorbent,...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: